Document Classification

Section Type: RESULTS

Text: Adverse events, which were more common among patients receiving paromomycin than among those receiving amphotericin B (6 % vs. 2 %, P = 0. 02), included transient elevation of aspartate aminotransferase levels (> 3 times the upper limit of the normal range) ; transient reversible ototoxicity (2 % vs. 0, P = 0. 20) ; and injection-site pain (55 % vs. 0, P < 0. 001) ; and in patients receiving amphotericin B, as compared with those receiving paromomycin, nephrotoxicity (4 % vs. 0, P < 0. 001), fevers (57 % vs. 3 %), rigors (24 % vs. 0, P < 0. 001), and vomiting (10 % vs. < 1 %, P < 0. 001).